Possible pathway for heart failure with preserved ejection fraction prevention and treatment: the angiotensin-converting enzyme inhibitor effect on endothelial function in comorbid patients

Aim      To evaluate the effect of perindopril on the endothelial function and levels of endothelial dysfunction markers in groups of patients with heart failure with preserved (HFpEF) and mid-range (intermediate) left ventricular ejection fraction (HFmrEF).

Material and methods  40 patients with HFpEF (n=20) and HFmrEF (n=20) were evaluated. At baseline, parameters of the morpho-functional state of large blood vessels and of microvessels were evaluated with photoplethysmography, and levels of E-selectin and endothelin-1 (ET-1) were measured. The patients were prescribed perindopril, and after 12 months of treatment, photoplethysmographic parameters and endothelial dysfunction markers were determined again.

Results After 12 months of the perindopril treatment, improvements in the endothelial function of both large blood vessels and microvessels were noted. The phase shift increased from 10.1 to 10.9 ms in the HFpEF group (р=0.001) and from 8.35 to 9.65 ms in the HFmrEF group (р=0.002). Furthermore, the occlusion index increased from 1.45 to 1.75 in patients with HFpEF (р=0.004) and from 1.5 to 1.75 in patients with HFmrEF (р=0.010). The Е-selectin concentration decreased in both groups, from 57.25 to 42.4 ng/ml (р=0.00008) and from 40.5 to 35.7 ng/ml (р=0.010) in patients with HFpEF and HFmrEF, respectively. The ET-1 concentration decreased from pg/ml (р=0.010) in patients with HFpEF whereas in patients with HFmrEF, there was no significant change in the ET-1 concentration after 12 months of the perindopril treatment.

Conclusion      At 12 months, the endothelial function improved and E-selectin and ET-1 levels decreased in patients with HFpEF and HFmrEF.

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

2. Streng KW, Nauta JF, Hillege HL, Anker SD, Cleland JG, Dickstein K et al. Non-cardiac comorbidities in heart failure with reduced, midrange and preserved ejection fraction. International Journal of Cardiology. 2018;271:132–9. DOI: 10.1016/j.ijcard.2018.04.001

3. van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L et al. Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. European Journal of Heart Failure. 2014;16(1):103–11. DOI: 10.1002/ejhf.30

4. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93(6):665–71. DOI: 10.1136/hrt.2005.068296

5. Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? European Journal of Heart Failure. 2017;19(12):1569–73. DOI: 10.1002/ejhf.1058

6. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertension Research. 2011;34(6):665–73. DOI: 10.1038/hr.2011.39

7. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive Oxygen Species in Inflammation and Tissue Injury. Antioxidants & Redox Signaling. 2014;20(7):1126–67. DOI: 10.1089/ars.2012.5149

8. Virdis A. Endothelial Dysfunction in Obesity: Role of Inflammation. High Blood Pressure & Cardiovascular Prevention. 2016;23(2):83–5. DOI: 10.1007/s40292-016-0133-8

9. Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications. Biomolecules. 2020;10(2):291. DOI: 10.3390/biom10020291

10. Hadi HAR, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vascular Health and Risk Management. 2007;3(6):853–76. PMID: 18200806

11. Lim HS, MacFadyen RJ, Lip GYH. Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart. Archives of Internal Medicine. 2004;164(16):1737–48. DOI: 10.1001/archinte.164.16.1737

12. Goossens GH. The Renin-Angiotensin System in the Pathophysiology of Type 2 Diabetes. Obesity Facts. 2012;5(4):611–24. DOI: 10.1159/000342776

13. Cao Z, Cooper ME. Pathogenesis of diabetic nephropathy: Pathogenesis of diabetic nephropathy. Journal of Diabetes Investigation. 2011;2(4):243–7. DOI: 10.1111/j.2040-1124.2011.00131.x

14. Fiordaliso F, Leri A, Cesselli D, Limana F, Safai B, Nadal-Ginard B et al. Hyperglycemia Activates p53 and p53-Regulated Genes Leading to Myocyte Cell Death. Diabetes. 2001;50(10):2363–75. DOI: 10.2337/diabetes.50.10.2363

15. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

16. Polverino F, Celli BR, Owen CA. COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulmonary Circulation. 2018;8(1):1–18. DOI: 10.1177/2045894018758528

17. Hoepers AT de C, Menezes MM, Fröde TS. Systematic review of anaemia and inflammatory markers in chronic obstructive pulmonary disease. Clinical and Experimental Pharmacology and Physiology. 2015;42(3):231–9. DOI: 10.1111/1440-1681.12357

18. Nedogoda SV, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS et al. Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. Clinical Drug Investigation. 2013;33(8):553–61. DOI: 10.1007/s40261-013-0094-9

19. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. European Heart Journal. 2005;26(14):1369–78. DOI: 10.1093/eurheartj/ehi225

20. Kryuchkova O.N., Kostyukova E.A., Lebed E.I., Itskova E.A., Zakharova M.A., Turna E.Yu. Effectiveness of perindopril and amlodipine combination in hypertensives with COPD. Russian journal of Cardiology. 2015;19(11):67–9. DOI: 10.15829/1560-4071-2014-11-67-69

21. Marketou ME, Zacharis EA, Koukouraki S, Stathaki MI, Arfanakis DA, Kochiadakis GE et al. Effect of angiotensin-converting enzyme inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. Journal of Human Hypertension. 2008;22(3):191–6. DOI: 10.1038/sj.jhh.1002310

22. Tousoulis D, Kourtellaris P, Antoniades C, Vasiliadou C, Papageorgiou N, Tentolouris C et al. Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patientswith coronary artery disease. International Journal of Cardiology. 2008;124(1):127–9. DOI: 10.1016/j.ijcard.2006.11.206

23. Nosrati SM, Khwaja S, El-Shahawy M, Massry SG. Effect of Angiotensin Converting Enzyme Inhibition by Perindopril on Proteinuria of Primary Renal Diseases. American Journal of Nephrology. 1997;17(6):511–7. DOI: 10.1159/000169180

24. Perkovic V, Ninomiya T, Arima H, Gallagher M, Jardine M, Cass A et al. Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study. Journal of the American Society of Nephrology. 2007;18(10):2766–72. DOI: 10.1681/ASN.2007020256

25. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. European Heart Journal. 2006;27(7):796–801. DOI: 10.1093/eurheartj/ehi809

26. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal. 2006;27(19):2338–45. DOI: 10.1093/eurheartj/ehl250

27. Safonova J.I., Kozhevnikova M.V., Danilogorskaya Yu.A., Zheleznykh E.A., Zektser V.Yu., Shchendrygina A.A. et al. Positive Effects of Perindopril on Microvascular Vessels in Patients With Chronic Heart Failure. Kardiologiia. 2020;60(8):65–70. DOI: 10.18087/cardio.2020.8.n1216